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Abstract     
Background: Interferon therapy is used as a line of  treatment of  chronic hepatitis C virus (HCV) in several areas of  the world 
including Egypt. 
Objective: Our aim was to investigate the value of  hepatic progenitor cells (HPCs) in predicting response of  patients with 
chronic HCV, genotype 4 to pegylated interferon (PEGIFN) plus ribavirin (RBV) therapy. 
Methods: Pre-treatment liver biopsies obtained from 110 patients with chronic HCV, genotype 4 were examined immunohisto-
chemically for HPCs using cytokeratin19. The mean number of  HPCs as ductular reaction (DR) and as isolated progenitor cells 
(IPCs) was counted in each case. The patients were classified into: those with sustained virological response (SVR) and those 
who did not achieve SVR. The results were compared between the two groups. Also, the relationships between HPCs and other 
clinico-pathologic variables were estimated using multivariate analysis. 
Results: The mean number of  HPCs was the only independent predictor of  therapeutic response, being significantly higher in 
non-responders (P = 0 for DR and P = 0.03 for IPCs). On the other hand, fibrosis stage and steatosis were the only independent 
factors which showed a significant direct association with the mean number of  HPCs in the form of  DR and IPCs (P = 0 for 
each).
Conclusion: The number of  HPCs provides prognostic information in chronic HCV since it is significantly associated with 
stage of  fibrosis. More importantly, it can be used as a marker to predict response of  patients with chronic HCV to PEGIFN 
plus RBV therapy.
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Hepatitis C virus (HCV) infection is one of  the most 
common health problems in Egypt with about 10% of  
the population infected1,2. The wide implementation of  
the recently introduced direct acting anti-virals is ham-
pered by their high cost and the possible resistance on 
long terms3. Therefore, the combined treatment with in-
terferon (IFN) and ribavirin (RBV) is still used as line of  
treatment of  HCV-infected patients4-6. Nevertheless, this 
therapy has a high rate of  non-response and is associated 
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with side effects7. Several host and viral factors have been 
investigated to be used as markers to predict the response 
of  chronic hepatitis C patients to the combined IFN and 
RBV treatment. Viral load was evaluated as a predictive 
factor by some studies with controversial results8-10 . The 
stage of  liver fibrosis was claimed to be a good predic-
tor of  treatment response in HCV infection9,11. However, 
this claim could not be supported by others8,10,12  Last but 
not least, was the genotyping of  IL-28 B which has been 
reported to be a strong predictor of  treatment outcome 
in HCV patients10,13-15. However, estimation of  this pa-
rameter needs sophisticated molecular techniques which 
are not usually available in general hospitals.
Hepatic progenitor cells (HPCs) are small cells located 
in the periportal region of  the liver16. Although the role 
of  HPCs in liver fibrogenesis has been extensively stud-
ied9,10,17,18, their value in predicting sustained virological 
response of  patients with HCV to treatment was not pre-
viously evaluated except in two reports. The first was Tsa-
mandas et al.17 on 77 patients with HCV of  different gen-
otypes. The second was performed on pediatric cases12 .
In the current study, we aimed to investigate the impor-
tance of  HPCs in predicting sustained virological re-
sponse in adult patient with chronic HCV genotype 4.
Material and methods
pecimen collection
This is a retrospective study which comprised random-
ly selected 110 needle liver biopsies from patients with 
chronic HCV admitted for anti-viral therapy during the 
period from January 2010 to December 2013. The inclu-
sion criteria included: 1) Patients older than 18 years and 
equal or less than 65 years. 2) HCV genotype 4. 3) Pre-
treatment liver biopsies. 4) Liver biopsies containing at 
least 5 portal tracts. The exclusion criteria were: 1) Coin-
fection with hepatitis B virus. 2) Presence of  other liver 
diseases. 3) Patients discontinued treatment. The study 
protocol was approved by the Research Ethical Commit-
tee, Faculty of  Medicine, Ain Shams University.
Demographic and laboratory data
The patients’ records were reviewed to retrieve the pa-
tient’s age, gender and pre-treatment serum level of  
HCV-RNA (estimated by quantitative polymerase chain 
reaction). The patients were classified into two groups: 
low viremia (< 600.000 IU/ML) and high viremia (≥ 
600.000 IU/ML)9 .
Therapeutic protocol
All 110 patients were treated with pegylated interferon 
(PEG IFN) alpha 2a and ribavirin (RBV) for a period 
of  48 weeks, following the protocol recommended by 
Derbala et al. (2005)19. The criteria for anti-viral therapy 
included age ≤ 65 years, elevated liver enzymes at least 
1.5 times the upper limit of  normal for 24 weeks and 
liver pathology with METAVIR stage of  fibrosis ≥ 120. 
Serum HCV-RNA was estimated while on treatment at 
weeks 12, 24, 48 and at 24 weeks after completing ther-
apy. Patients were categorized according to Rizk et al.10 
into two groups: responders including patients with sus-
tained virological response (SVR) who had undetectable 
serum HCV-RNA by PCR assay 24 weeks following stop-
ping therapy after achieving end of  treatment. The sec-
ond group (non-responders) consisted of  patients who 
had relapse (reappearance of  the serum HCV-RNA after 
end of  treatment), patients with viral breakthrough (reap-
pearance of  serum HCV-RNA while still on therapy after 




Hematoxylin and Eosin-stained and Masson Tri-
chrome-stained tissue sections were examined for grad-
ing of  the necroinflammatory activity (A) and staging of  
fibrosis (F) according to METAVIR scoring system 21. 
For statistical analysis; necroinflammatory activity was 
classified into A1 and A2+A3, also stage of  fibrosis was 
grouped as: F1 + F2 and F3 + F4. No A 0 or F 0 cases 
were included in the study. Steatosis was considered as 




Four micron-thick tissue sections were cut from the par-
affin blocks for all the 110 liver biopsies onto positively 
charged slides. These sections were immunostained for 
cytokeratin 19 (CK19) using ready to use CK19 mono-
clonal mouse antibody (Cat. No 319-M18, cell Marque, 
Rocklin, USA). CK19 was considered as the most sensi-
tive marker for immunohistochemical demonstration of  
HPCs17,23. The immunostaining study was performed by 
applying avidin-biotin detection kit (Zymed, San Francis-
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co , USA) and following the technique of  Hsu et al.24, 
using an automated machine (Ventana Medical Systems, 
Inc. Tucson, Arizona, USA), according to the manufac-
turer protocol. Bile ducts in the liver biopsies were used 
as a positive built- in control. Negative control was per-
formed by following the same steps except for adding 
BSA in PBS instead of  the primary antibody. For con-
trol purposes, 10 needle liver biopsies obtained from liver 
donors with normal histology were immunostained for 
CKl9.
 
Interpretation and quantification of  immunostain-
ing 
Brownish cystoplasmic staining was considered positive. 
According to Roskams et al.25, positively stained HPCs 
were searched for in the periportal area where they form 
ductular reaction (DR) and in the liver parenchyma where 
they are scattered as isolated progenitor cells (IPCs). For 
each liver biopsy, the whole tissue section was examined 
under higher power magnification × 400 to count man-
ually the number of  DR and IPCs separately. Then, the 
mean number of  each cell type per one high power field 
(HPF) was taken17.
Statistical analysis
IBM SPSS statistics (V. 23.0, IBM Corp., USA, 2015) was 
applied for data analysis. Quantitative data were expressed 
as range and means ± SD. Categorical variables were giv-
en as numbers and percentages. Relationships between 
HPC expression and clinicopathologic variables and com-
parison between responders and non-responders regard-
ing these variables were performed by using one-paired 
student t test for numerical variables and Chi square test 
for categorical variables. Multivariate analysis was then 
done to identify independent determinants. Correlation 
between the values of  DR and IPCs was estimated by 
applying Spearman’s rank correlation coefficient test. For 
all tests, P value less than 0.05 was considered statistically 
positive.
Results
Patients’ data and treatment response
The 110 liver biopsies were obtained from 96 males 
(87.3%) and 14 females (12.7%). The ages of  patients 
ranged between 21 and 62 years (mean 44.0 ± 8.03). Sev-
enty two had low viremia (65.5%) and 38 had high vire-
mia (34.5%). SVR was achieved in 47 out of  the 110 pa-
tients (responders) (42.7%). The non-responders were 63 
patients(57.3%). They consisted of  11 relapsers, 25 with 
viral breakthrough and 27 not achieved response.
Histologic data
The necroinflammatory disease activity (A) was found to 
be A1 in 61 (55.5%), A2 in 32 (29%) and A3 in 17 cases 
(15.5%). Fibrosis stage (F) was: F1 (38, 34.5%), F2 (28, 
25.5 %), F3 (34, 30.9%) and F4 (10, 9.1%). Steatosis was 
absent in 62 (56.4%) and present in 48 cases (43.6%). 
HPC expression
Six of  the 10 normal liver biopsies showed scanty HPCs 
in the form of  IPCs (Figure 1).  On the other hand; all 
110 liver biopsies with chronic HCV showed HPCs as 
DR and IPCs (Figure 2 & 3). The number of  DR ranged 
between 1 and 17.9 with a mean 4.7 ± 3.0. The number 
of  IPCs ranged between 0.6 and 10.3 with a mean 3.7 ± 
2.1.
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Figure (1):   A case of normal control liver tissue showed scanty isolated 
hepatic progenitor cells (CK 19; original magnification  x400). 
Comparison between responders and non-respond-
ers  
The mean number of  HPCs expressed as DR was higher 
in non-responders (5.8) than responders (3.3). The dif-
ference was highly significant (t = - 4.5, P = 0). Also, 
the mean number of  IPCs was significantly higher in the 
non-responders (4.1) than responders (3.1) (t = -2.6, p 
= 0.005). Conversely; no difference between responders 
and non-responders regarding the mean age of  patients, 
gender, level of  viremia, grade of  disease activity, stage of  
fibrosis and status of  steatosis (Table 1). By applying Wil-
coxon Rank Sum test for multivariate analysis, we found 
that HPCs in the form of  DR and IPCs were indepen-
dent predictors of  therapeutic response (Z = - 4.5, P = 0, 
Z = - 2.2, P = 0.03; respectively).
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Relationship between HPC expression and other 
variables in all cases
For DR, the mean number of  positive cells was signifi-
cantly higher in more active cases (t = - 2.5, P = 0.007), 
in more advanced stages of  fibrosis (t = - 6.7, P = 0) and 
cases showing steatosis (t = - 4.5, P = 0).
Table (1): Comparison between responders and non-responders 
Factor Responders  (N = 47) 
Non-responders  
(N = 63) t/χ
2 P 
Mean age  42.6 45.0 t = -1.1 NS 
Gender     
χ2 = 0.3 NS Male 42 54 
Female 5 9 
Viremia     
χ2 = 1.7 NS Low 34 38 
High 13 25 
Activity     
χ2 = 0.1 NS A1 27 34 
A2 + 3 20 29 
Fibrosis     
χ2 = 1.2 NS F1 + 2 31 35 
F3 + 4 16 28 
Steatosis     
χ2 = 0.9 NS Absent 29 33 
Present 18 30 
Mean DR 3.3 ± 1.6 5.8 ± 3.4 t = -4.5 0 
Mean IPC 3.1 ± 1.7 4.1 ± 2.3 t = -2.6 0.005 
DR: Ductular reaction, IPC: Isolated progenitor cells, NS: No significant 




Table (2): Relationship between HPC expression and other clinico-
pathologic factors in 110 cases with chronic hepatitis C 
Factor Number of cases 
DR IPCs 
Mean t p Mean t p 
Age (years)               
≤ 40 35 4.9 -0.4 NS 3.5 -0.7 NS 
> 40 74 4.7     3.8     
Gender               
Male 96 3.4 -1.3 NS 3.6 -0.9 NS 
Female 14 2.8     4.2     
Viremia           
Low 72 4.7 0.1 NS 3.6 -0.6 NS 
High 38 4.7     3.9     
Activity               
A1 61 4.1 -2.5 0.007 3.4 -1.6 NS 
A2 +A 3 49 5.5     4.1     
Fibrosis               
F1 +F 2 66 3.4 -6.7 0 3.0 -4.9 0 
F3 +F 4 44 6.7      
Steatosis               
 
Absent  
Present 48 6.1     4.6     
HPC: hepatic progression cells; DR: Ductular reaction, IPC: Isolated progenitor cells 
NS: No significant  
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A1 61 4.1 -2.5 0.007 3.4 -1.6 NS 
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62 3.7 -4.5    0   3.0    -4.2    0
IPCs were significantly more expressed in specimens with 
later stages of  fibrosis (t = -4.9, P = 0) and those having 
steatosis (t = -4.2, P = 0). Both DR and IPCs were not 
related to the patient’s age, gender or level of  viremia (Ta-
ble 2). Multivariate regression analysis showed that stage 
of  fibrosis and steatosis were independent factors that 
significantly associated with the number of  DR (F ratio = 
10.8, P = 0) and IPCs (F ratio = 6.3, P = 0).
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Figure (2): A case of chronic HCV showed a high number of hepatic 
progenitor cells expressed as ductular reaction and isolated 
progenitor cells (CK 19; original magnification  x400). 
 
 
Figure (3):  A case of chronic HCV showed a relatively low number 
of hepatic progenitor cells in the form of isolated progenitor cells 
and ductular reaction (CK 19; original magnification  x400). 
 
 
Figure (2): A case of chronic HCV showed a high number of hepatic 
progenitor c lls expressed as ductular reaction and isolated 
progenitor ce ls (CK 19; original magnif cation  x400). 
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Correlation between DR and IPCs
The means of  DR cells and IPCs showed a highly signifi-
cantly direct correlation (r = 0.8, P = 0) (Figure 4).
 
Figure (4):  A highly significantly direct correlation between 
the number of ductular reaction (DR) and isolated progenitor 
cells (IPCs) (r = 0.8, P = 0). 
Discussion
Several studies investigated a series of  viral and host 
factors to assess their potential value in prediction of  
response to interferon therapy in patients with chronic 
hepatitis C26-30. Nevertheless, it has been noted that: First, 
most of  these studies are controversial with no agreement 
on a reliable predictor of  treatment response. Second, re-
ported articles investigating the predictors of  sustained 
virological response (SVR) in adult patients with HCV 
genotype 4 which is the most common type in Egypt, are 
very few10,31. Third, no previous reports analyzed the role 
of  HPCs in predicting response of  adult HCV patients to 
therapy, except that of  Tsamandas et al.17 who studied 77 
cases with various genotypes. These observations stim-
ulated us to perform this work in an attempt to explore 
the role of  HPCs in predicting SVR in 110 patients with 
chronic HCV genotype 4.
Sixty three of  the 110 patients included in the study 
(42.7%) yielded SVR. This is in line with Rizk et al.10 who 
obtained SVR in 45.5% of  Egyptian patients with HCV, 
genotype 4. Higher levels of  SVR (58%) were reported 
in patients with genotype 39  and lower levels (36%) were 
observed in patients genotype 18 . These data support 
the conclusion of  Jang and Chung32  that genotype 1 re-
sponds weakly to treatment, while genotype 3 responds 
better.
The current study confirmed previous reports that 
demonstrated HPCs in HCV-infected liver biopsies in 
the form of  DR as well as IPCs18,33 . More importantly, 
we found that responders (SVR) had a significantly low-
er number of  HPCs (both DR and IPCs) than non-re-
sponders (Non-SVR). This result implies that assessment 
of  HPCs in the pre-treatment liver biopsies of  HCV pa-
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tients may be helpful in predicting the response to treat-
ment. Similar data have been previously obtained by Tsa-
mandas et al.17  who did not give explanation for such as 
important finding. HCV infection is known to induce cell 
cycle arrest and thus inhibit proliferation of  normal ma-
ture hepatocytes. This inhibition promotes replication of  
HPCs as an alternative pathway34,35. Accordingly, we can 
speculate that in our patients who failed to achieve SVR, 
HCV protein which resisted response to therapy, was also 
able to mediate impairment of  the cell cycle of  mature 
liver cells and eventually contributes to HPC prolifera-
tion. It was interesting to compare our results with those 
of   D’Ambrosio et al.33 and Noritake et al.18. Both studies 
estimated the immune expression of  HPCs in pre-treat-
ment and post-treatment liver biopsies of  chronic HCV 
to evaluate the effect of   interferon therapy on the expres-
sion of  these cells. The authors found that the number of  
HPCs significantly decreased after SVR. Noritake et al.18  
proposed that eradication of  the virus could improve the 
HCV-related impairment of  mature hepatocyte prolifer-
ation with consequent inhibition of  HPC replication. Al-
though the aim and design of  the afore-mentioned two 
reports were different from ours, their conclusions are 
consistent with our findings.
Unexpectedly, there was no significant difference between 
responders and non-responders regarding the stage of  fi-
brosis. This finding which agrees with previous studies8, 
10,12,15  indicates that cases with early stages of  fibrosis may 
not respond to therapy and cases with late stages may 
respond. This is supported by the report of  D’Ambrosio 
et al.33   who studied the benefit of  SVR in HCV patients 
with cirrhosis by evaluating pre- and post-treatment liver 
biopsies. The authors found that 61% of  patients yield-
ed a decrease of  at least one METAVIR stage point in 
post-treatment biopsies. Another important observation 
in the present study was that the number of  HPCs was sig-
nificantly higher in later stages of  fibrosis. This confirms 
several previous studies9,10,17,18  and indicates that HPCs 
participate either directly or indirectly through cross talk 
with  stellate cells in the process of  hepatic fibrogenesis. 
We investigated the relationship between stellate cells and 
HPCs in chronic HCV in a previous report36.
Steatosis is one of  the hallmarks in the liver biopsies of  
chronic HCV37. In the current work, we observed that 
steatosis had no impact on response to therapy to HCV 
infection. This is in line with previous studies9,33,38  On 
the other hand, we noted that the number of  HPCs (both 
DR and IPCs) was significantly higher in biopsies having 
steatosis. This is in agreement with Clouston et al.39  who 
reported that steatosis induces proliferative blockade in 
HCV-infected hepatocytes resulting into promotion of  
HPC replication.
The pre-treatment viral load has been assumed to be 
a useful predictor of  response to treatment in chronic 
HCV9 .  However, we and others8,10 could not support 
such an assumption. Gunal et al.11 suggested that this was 
due to small number of  their cases and they were fol-
lowed up by different PCR techniques. Our own view is 
that the response to HCV treatment may be related to the 
virulence power of  the virus rather than its quantitative 
value in blood.
In the present study, it was interesting to note that DR 
and IPCs are always present together in all 110 liver bi-
opsies. Furthermore, the number of  both types of  HPCs 
showed a highly significant direct correlation (r = 0.8, P 
= 0).This result was also reported by Clouston et al.39  and 
El-Araby et al.12  who claimed that IPCs may represent 
the earlier stage of  HPCs which is followed by DR for-
mation.
Finally, our study may have some limitations. First, since 
it was retrospective, the cases were selective rather than 
consecutive according to the inclusion and exclusion cri-
teria. So, selection bias couldn’t be excluded. Second, the 
number of  specimens was relatively small. However, it 
adequately represents the sample size required to produce 
specific statistical power. Third, the use of  a single mark-
er for HPCs may be considered a limitation. Neverthe-
less, CK19 was considered as the most sensitive marker 
for immunohistochemical identification of  HPCs17,23. In 
spite of  these limitations, the current study has the power 
of  having all cases from one center with the same treat-
ment protocols.
Conclusion 
The present study is the first to explore the role of  HPCs 
in predicting response to IFN therapy in adult chronic 
HCV patients with genotype 4. The highly significant dif-
African Health Sciences Vol 19 Issue 1, March, 2019 1419
ference between responders and non-responders regard-
ing the number of  HPC expression indicates that it can be 
used as an independent predictor to response to therapy 
in patients with chronic HCV, genotype 4. Undoubtedly, 
further studies on larger number of  cases are mandatory 
before recommending immuno histochemical estimation 
of  HPCs to predict response to HCV treatment.
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